Despite the large number of biologics currently available for moderate-to-severe psoriasis,
poor adherence and persistence to therapy represent the main issues for both the clinical …

Introduction Significant advances in psoriasis treatment have taken place since the
introduction of biologics. Tumor necrosis factor inhibitors were the first class of biologics …

Introduction Treatment with biologics often leads to clearance of psoriasis. However, some
patients do repeatedly fail to respond and/or lose an achieved response (treatment …

Identifying patient characteristics associated with achieving treatment response to biologics
in patients with psoriasis could prevent expensive switching between biologics. The aim of …

The real‐world treatment landscape for patients with moderate‐to‐severe psoriasis
receiving systemic therapies in Japan is not well understood. This study describes the …

This work describes the fabrication of two composite nanofibers systems containing
polyacrylonitrile polymer (PAN), Multiwall carbon nanotubes (MWCNT) and Titania (TiO 2) …

Background and objectives Psoriasis is a common skin disorder with a high physical and
psychological burden for patients. Up to 30% of the patients are candidates for a systemic …

Abstract Background and Objective Long-acting injectable antipsychotics (LAIs) are
associated with better treatment adherence and persistence than oral antipsychotics (OAPs) …

Introduction Rheumatoid arthritis (RA), psoriatic arthritis (PsA) and psoriasis (PSO) are
chronic inflammatory diseases that have a substantial impact on patients' health. This …

Introduction To investigate drug survival for biologic disease-modifying antirheumatic drugs
(bDMARDs) in a real-world cohort of German adult biologic-naïve patients with psoriatic …